CIK 0001404281 · Non-accelerated filer<br>Smaller reporting company
Eledon Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 949-238-8090
- Business address
- 19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
- Former names
- Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 3,000 shares at $11.25 ($33,750)
- 10-Q Report Quarterly Report
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- 4 Open-market sale Chief Operating Officer sold 13,500 shares at $14.01 ($189,135)
- 4 Open-market sale Chief Financial Officer sold 4,668 shares at $13.13 ($61,291)
- 4 Open-market sale Chief Financial Officer sold 2,158 shares at $12.96 ($27,968)
- 10-Q Report Quarterly Report
- 4 Open-market sale President and CEO sold 12,564 shares at $13.70 ($172,127)
- 4 Option exercise President and CEO acquired 10,000 shares (option exercise)
- 4 Open-market sale 10% owner sold 3,566 shares at $14.26 ($50,844)
- 4 Open-market sale 10% owner sold 48,472 shares at an average $14.32 ($694,194)
- 4 Open-market sale President and CEO sold 16,000 shares at an average $13.77 ($220,240)
Page 26 of 31 · 616 filings